Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

INZY - Inozyme Pharma Inc


IEX Last Trade
5.54
0   0%

Share volume: 156,785
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$5.54
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
2.59%
1 Month
-3.48%
3 Months
18.12%
6 Months
-15.55%
1 Year
11.47%
2 Year
81.64%
Key data
Stock price
$5.54
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.69 - $7.80
52 WEEK CHANGE
$0.15
MARKET CAP 
347.549 M
YIELD 
N/A
SHARES OUTSTANDING 
62.734 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.93
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$271,408
AVERAGE 30 VOLUME 
$325,723
Company detail
CEO:
Region: US
Website: inozyme.com
Employees: 60
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

we are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. our area of expertise is in disorders of paradoxical mineralization and our lead drug is an enzyme replacement therapy in pre-clinical development.

Recent news